Muscle SorenessNCT06320327
Topical CBD's Effects on Soreness and Performance
A study testing Cannabidiol cream in people with Muscle Soreness, run by Joseph Pastina at 2 sites in United States.
Trial summary
Exercise-induced muscle damage (EIMD) results from unaccustomed exercise and can lead to delayed onset muscle soreness (DOMS). Impairments associated with EIMD and DOMS can result in moderate-to-severe discomfort and hindered performance. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Muscle Soreness
- What is being tested?
- Cannabidiol cream
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 2 sitesUnited States
- Study dates
- 23 Aug 2022to 30 Apr 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Physically healthy
- Age 18-45
- Available for 5 sessions over the span of 2 weeks
- Untrained (have not been participating in a structured resistance training routine for the past 2 months that includes 2 days of lower body resistance training per week)
Who cannot join
- Have not suffered a lower body injury in the previous 3 months
- Be allergic to any ingredients within the CBD or placebo creams (ingredients listed in informed consent form)
- Be pregnant
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Seaton Center Building
Lexington, Kentucky, 40502
Multidisciplinary Science Building
Lexington, Kentucky, 40536
About this study
Official title: The Effects of Cannabidiol (CBD) Cream on Delayed Onset Muscle Soreness (DOMS and Performance After Exercise
Exercise-induced muscle damage (EIMD) results from unaccustomed exercise and can lead to delayed onset muscle soreness (DOMS). Impairments associated with EIMD and DOMS can result in moderate-to-severe discomfort and hindered performance. Recently, a compound derived from the cannabis plant, cannabidiol (CBD), has been used as a recovery tool for EIMD and DOMS. Despite the rising popularity of CBD products, their effectiveness in mitigating EIMD and DOMS is unknown. Specifically, to the investigators' knowledge, no clinical trials have been completed to assess the effects of topical CBD cream application on soreness, recovery and performance.
Therefore, the purpose of the present study was to investigate the effects of CBD cream on DOMS and performance after an intensive lower-body exercise protocol. Specifically, the study's aims were:
Read more
Aim 1: To assess the effect of topical CBD cream administration on muscle soreness following fatiguing exercise.
Hypothesis 1: CBD cream would decrease perceived muscle soreness when compared to a placebo or control (no cream) group.
Aim 2: To assess the effect of topical CBD cream administration on muscular performance following fatiguing exercise.
Hypothesis 2: Recovery of muscular power would be quicker when CBD cream is applied, compared to a placebo or control (no cream) group.
Aim 3: To assess if topical CBD cream has a localized (if any) or systemic effect on muscle soreness.
Hypothesis 3: Improvements in muscle soreness would only be observed in localized muscles around where the CBD cream was applied.
Read the detailed description
This study is a randomized, double-blind, placebo-controlled experiment examining if CBD cream impacts recovery after exercise. It will be investigated whether or not the potential effects of CBD cream are localized or systemic within the lower body muscles (quadriceps and hamstrings). Furthermore, the study will examine if these potential effects on recovery impact the expected decrements on lower body performance in the days following an intense exercise bout. Overall, the main objective is to determine whether or not CBD cream is an effective recovery method for those who are experiencing DOMS.
Participants will be recruited from volunteers who reside in the Lexington area. Those who participate within the study will be randomly placed into one of three groups by the PI, Dr. Stuart Best: a group that will apply the CBD cream (Group 1), a group that will apply the placebo moisturizer cream (Group 2), or a control group that does not participate in any cream-related procedures (Group 3).
The research participants and research personnel conducting the testing will be blinded to who is in the CBD and placebo groups throughout the study. Furthermore, the PI, who will not participate in any form of testing, will also be responsible for the storage and distribution of the CBD and placebo creams during the study. Those in Group 3 (the control group) will be aware that they are in the control group, as they will be skipping the steps involving cream application. The protocols for Group 1 and Group 2 will be identical and the respective cream will be made available to the testers and participants in identical containers.
A summary of the participant groups is shown below:
Group 1 - CBD Group; This group will apply the CBD cream in accordance with the manufacturer's recommendations throughout the study. Application procedures are described in a section below.
Group 2 - Placebo Group; This group will apply a placebo moisturizer cream that will match the scent, volume, and viscosity of the CBD cream. Application procedures are described in a section below..
Group 3 - Control Group; This group will not apply any cream and will skip all cream-related procedures during the study. During the time that would be designated for cream-related procedures, the control group will rest; this rest period will match the durations of the cream-related procedures for Groups 1 and 2 to keep the delivery of procedures as controlled as possible between groups.
Participants will complete five sessions over the span of 7-11 days. Sessions 1 and 2 will be separated by 3-7 days to wash-out any potential soreness from baseline testing, and Sessions 2-5 will be separated by 24-hr each. A session outline is described below:
Session 1: Anthropometric data, baseline measurements for isokinetic peak torque (PT) and countermovement jump (CMJ) as well as familiarization with the pressure-pain threshold (PPT) test are established. Prior to baseline testing, familiarization with the CMJ and PT instruments and procedures are included during this introductory session.
Session 2 (3-7 days after Session 1): The time between Sessions 1 and 2 ensured each participant began the Session 2 without any residual muscle damage or soreness from Session 1. Participants will complete a digital questionnaire to monitor and evaluate soreness and recovery. Questionnaires will be administered using Research Electronic Data Capture (REDCap) on the investigator's personal computer. Participants will then complete a PPT test, which will serve as their baseline measurement, followed by a fatiguing exercise protocol (FP) designed to induce muscle damage and soreness. The FP consists of repeated maximal effort concentric and eccentric muscle actions at the knee joint (5 sets, 10 reps, 30 seconds rest for both concentric/eccentric knee extension/flexion and eccentric/concentric knee extension/flexion, respectively). A Post-FP questionnaire will be completed to monitor changes in muscle soreness after the FP, followed by the cream application/sitting rest procedures (C/R) for each participant's respective group. The session concludes with a questionnaire (Post C/R) to evaluate the effects of cream/rest, another PPT, and a CMJ assessment.
Session 3 and 4 (24- and 48-hr after Session 2): Sessions 3 and 4 will utilize identical procedures. Participants will complete a Pre-Session questionnaire to monitor soreness and recovery. Then, PPT and CMJ tests are completed. Participants then apply cream or have seated rest according to the respective protocol for their group. After the cream application/sitting procedure occur, participants complete a follow-up Post C/R questionnaire. Lastly, PPT and CMJ are completed again by the participant.
Session 5 (72-hr after Session 2): Session 5 repeats the research procedures of Session 1, with the exclusion of anthropometric testing. To complete Session 5, as well as their participation in the study, each participant will complete a Post-Study questionnaire
Application Procedures:
Cream application procedures will be the same for both CBD and placebo groups, with only the type of cream applied differing between the two groups. Participants will have their quadriceps marked to represent a 'cream application zone'. Similar to the quadriceps PPT, the markings made on the midline of the anterior leg midway between the anterior superior iliac spine (ASIS) and the superior border of the patella will be utilized. However, two new markings will be created to serve as a superior and inferior site: 1) being one-third of the distance between the ASIS and the superior border of the patella; and, 2) two-thirds of the distance between the ASIS and the superior border of the patella. Each participant will first apply the cream to the most superior site on the dominant leg in a clockwise rhythm at a standardized cadence (50 beats·min^-1) for 30 seconds. The participant will then be instructed to proceed inferiorly until all three sites are completed. For each site, participants will be instructed to apply approximately one-third of the total quantity of cream per container. At the conclusion of this process, participants will be told to finish applying any residual cream remaining in the containers across the entire area of cream application. To assess the localized vs systemic effects of CBD cream, cream will only be applied to the quadriceps in both the CBD and placebo groups. Participants within the control group will be instructed to sit in a relaxed position for 3 minutes. This duration has been chosen because it matches the total time of the cream application for CBD and placebo groups.
- Conditions
- Muscle Soreness
- Being tested
- Cannabidiol cream, Placebo cream
- Keywords
- Exercise, Cannabidiol cream
- Medical subject headings
- Myalgia, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cannabidiol creamOther
Also called Myaderm Advanced RX10 Fast Acting Relief Cream
Group 1 will be administered the recommended quantity of CBD cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method).
Placebo creamOther
Also called Gold Bond Diabetics' Dry Skin Relief Lotion
Group 2 will be administered the recommended quantity of placebo cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method).
| Study group | Role | What they receive |
|---|---|---|
| CBD Group | Experimental | This group will apply the CBD cream in accordance with the manufacturer's recommendations at designated time points throughout the study. Receives: Other: Cannabidiol cream |
| Placebo Group | Placebo comparator | This group will apply a placebo moisturizer cream that will match the scent, volume, and viscosity of the CBD cream. Receives: Other: Placebo cream |
| Control Group | No intervention | This group will not apply any cream and will skip all cream-related procedures during the study. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Vertical Jump Test
The vertical jump, or countermovement jump (CMJ), test will utilize the ForceDecks Dual Force Plate System by Vald Performance to measure peak force production and vertical jump height (one plate for each leg; sampling frequency = 1,000 Hz).
Measured: Baseline and immediately post exercise, then 24, 48, and 72 hours post-exercise (pre- and post-cream/rest).
Secondary outcomes (2)
Peak Isokinetic Torque Test
The Peak Isokinetic Torque Test will use the Biodex, an isokinetic dynamometer to establish measures for concentric and eccentric peak isokinetic torque during knee extension and knee flexion.This test requires a maximal effort on 5 repetitions, and the highest isokinetic torque value of the five repetitions will be documented.
Measured: Baseline and Session 5 (72 hours post-exercise)
Pressure-Pain Threshold Test
The pressure-pain threshold test (PPT) is designed to provide a quantitative measure of muscular sensitivity. It will be used to provide a subjective measure of soreness. The test utilizes a compact digital algometer equipped with a 1-cm2 rubber tip that, when pressed against a surface, will provide a pressure reading as force is applied to a surface. The reading will be provided in Newtons (N) and converted to kilopascals (kPa) for analysis (1 N/cm2 = 10 kPa). For the PPT, the subject will have four markings (indicated below) and pressure will be applied to each marking using the algometer using a standardized method. The subject will indicate discomfort rather than pressure, and that value will be documented.
Measured: Baseline and immediately post exercise, then 24, 48, and 72 hours post-exercise (pre- and post-cream/rest).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2024
- Study start23 Aug 2022
- Primary completion27 Apr 2023
- Study completion30 Apr 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Muscle SorenessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Joseph Pastina
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Joseph Pastina, University of Kentucky
- Investigators
- Stuart A Best, PhD, Principal investigator, University of Kentucky
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06320327
- Sponsor's protocol ID
- 80177
- Status last verified
- Mar 2024
- First submitted
- 13 Mar 2024
- Last updated
- 20 Mar 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Pastina JT, Abel MG, Bollinger LM, Best SA. Topical Cannabidiol Application May Not Attenuate Muscle Soreness or Improve Performance: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study. Cannabis Cannabinoid Res. 2025 Jun;10(3):445-456. doi: 10.1089/can.2024.0012. Epub 2024 Jul 9.
PubMed 38980809
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Cannabidiol (CBD) Cream on Delayed Onset Muscle Soreness (DOMS and Performance After Exercise
- ClinicalTrials.gov ID
- NCT06320327
- Acronym / sponsor ID
- 80177
- Conditions
- Muscle Soreness
- Keywords
- Exercise, Cannabidiol cream
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Joseph PastinaUniversity, hospital or other
- Study start
- 23 Aug 2022 (actual)
- Primary completion
- 27 Apr 2023 (actual)
- Study completion
- 30 Apr 2023 (actual)
- First posted
- 20 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Exercise-induced muscle damage (EIMD) results from unaccustomed exercise and can lead to delayed onset muscle soreness (DOMS). Impairments associated with EIMD and DOMS can result in moderate-to-severe discomfort and hindered performance. Recently, a compound derived from the cannabis plant, cannabidiol (CBD), has been used as a recovery tool for EIMD and DOMS. Despite the rising popularity of CBD products, their effectiveness in mitigating EIMD and DOMS is unknown. Specifically, to the investigators' knowledge, no clinical trials have been completed to assess the effects of topical CBD cream application on soreness, recovery and performance.
Therefore, the purpose of the present study was to investigate the effects of CBD cream on DOMS and performance after an intensive lower-body exercise protocol. Specifically, the study's aims were:
Aim 1: To assess the effect of topical CBD cream administration on muscle soreness following fatiguing exercise.
Hypothesis 1: CBD cream would decrease perceived muscle soreness when compared to a placebo or control (no cream) group.
Aim 2: To assess the effect of topical CBD cream administration on muscular performance following fatiguing exercise.
Hypothesis 2: Recovery of muscular power would be quicker when CBD cream is applied, compared to a placebo or control (no cream) group.
Aim 3: To assess if topical CBD cream has a localized (if any) or systemic effect on muscle soreness.
Hypothesis 3: Improvements in muscle soreness would only be observed in localized muscles around where the CBD cream was applied.
Detailed description
This study is a randomized, double-blind, placebo-controlled experiment examining if CBD cream impacts recovery after exercise. It will be investigated whether or not the potential effects of CBD cream are localized or systemic within the lower body muscles (quadriceps and hamstrings). Furthermore, the study will examine if these potential effects on recovery impact the expected decrements on lower body performance in the days following an intense exercise bout. Overall, the main objective is to determine whether or not CBD cream is an effective recovery method for those who are experiencing DOMS.
Participants will be recruited from volunteers who reside in the Lexington area. Those who participate within the study will be randomly placed into one of three groups by the PI, Dr. Stuart Best: a group that will apply the CBD cream (Group 1), a group that will apply the placebo moisturizer cream (Group 2), or a control group that does not participate in any cream-related procedures (Group 3).
The research participants and research personnel conducting the testing will be blinded to who is in the CBD and placebo groups throughout the study. Furthermore, the PI, who will not participate in any form of testing, will also be responsible for the storage and distribution of the CBD and placebo creams during the study. Those in Group 3 (the control group) will be aware that they are in the control group, as they will be skipping the steps involving cream application. The protocols for Group 1 and Group 2 will be identical and the respective cream will be made available to the testers and participants in identical containers.
A summary of the participant groups is shown below:
Group 1 - CBD Group; This group will apply the CBD cream in accordance with the manufacturer's recommendations throughout the study. Application procedures are described in a section below.
Group 2 - Placebo Group; This group will apply a placebo moisturizer cream that will match the scent, volume, and viscosity of the CBD cream. Application procedures are described in a section below..
Group 3 - Control Group; This group will not apply any cream and will skip all cream-related procedures during the study. During the time that would be designated for cream-related procedures, the control group will rest; this rest period will match the durations of the cream-related procedures for Groups 1 and 2 to keep the delivery of procedures as controlled as possible between groups.
Participants will complete five sessions over the span of 7-11 days. Sessions 1 and 2 will be separated by 3-7 days to wash-out any potential soreness from baseline testing, and Sessions 2-5 will be separated by 24-hr each. A session outline is described below:
Session 1: Anthropometric data, baseline measurements for isokinetic peak torque (PT) and countermovement jump (CMJ) as well as familiarization with the pressure-pain threshold (PPT) test are established. Prior to baseline testing, familiarization with the CMJ and PT instruments and procedures are included during this introductory session.
Session 2 (3-7 days after Session 1): The time between Sessions 1 and 2 ensured each participant began the Session 2 without any residual muscle damage or soreness from Session 1. Participants will complete a digital questionnaire to monitor and evaluate soreness and recovery. Questionnaires will be administered using Research Electronic Data Capture (REDCap) on the investigator's personal computer. Participants will then complete a PPT test, which will serve as their baseline measurement, followed by a fatiguing exercise protocol (FP) designed to induce muscle damage and soreness. The FP consists of repeated maximal effort concentric and eccentric muscle actions at the knee joint (5 sets, 10 reps, 30 seconds rest for both concentric/eccentric knee extension/flexion and eccentric/concentric knee extension/flexion, respectively). A Post-FP questionnaire will be completed to monitor changes in muscle soreness after the FP, followed by the cream application/sitting rest procedures (C/R) for each participant's respective group. The session concludes with a questionnaire (Post C/R) to evaluate the effects of cream/rest, another PPT, and a CMJ assessment.
Session 3 and 4 (24- and 48-hr after Session 2): Sessions 3 and 4 will utilize identical procedures. Participants will complete a Pre-Session questionnaire to monitor soreness and recovery. Then, PPT and CMJ tests are completed. Participants then apply cream or have seated rest according to the respective protocol for their group. After the cream application/sitting procedure occur, participants complete a follow-up Post C/R questionnaire. Lastly, PPT and CMJ are completed again by the participant.
Session 5 (72-hr after Session 2): Session 5 repeats the research procedures of Session 1, with the exclusion of anthropometric testing. To complete Session 5, as well as their participation in the study, each participant will complete a Post-Study questionnaire
Application Procedures:
Cream application procedures will be the same for both CBD and placebo groups, with only the type of cream applied differing between the two groups. Participants will have their quadriceps marked to represent a 'cream application zone'. Similar to the quadriceps PPT, the markings made on the midline of the anterior leg midway between the anterior superior iliac spine (ASIS) and the superior border of the patella will be utilized. However, two new markings will be created to serve as a superior and inferior site: 1) being one-third of the distance between the ASIS and the superior border of the patella; and, 2) two-thirds of the distance between the ASIS and the superior border of the patella. Each participant will first apply the cream to the most superior site on the dominant leg in a clockwise rhythm at a standardized cadence (50 beats·min^-1) for 30 seconds. The participant will then be instructed to proceed inferiorly until all three sites are completed. For each site, participants will be instructed to apply approximately one-third of the total quantity of cream per container. At the conclusion of this process, participants will be told to finish applying any residual cream remaining in the containers across the entire area of cream application. To assess the localized vs systemic effects of CBD cream, cream will only be applied to the quadriceps in both the CBD and placebo groups. Participants within the control group will be instructed to sit in a relaxed position for 3 minutes. This duration has been chosen because it matches the total time of the cream application for CBD and placebo groups.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| CBD Group | Experimental | Other: Cannabidiol creamThis group will apply the CBD cream in accordance with the manufacturer's recommendations at designated time points throughout the study. |
| Placebo Group | Placebo comparator | Other: Placebo creamThis group will apply a placebo moisturizer cream that will match the scent, volume, and viscosity of the CBD cream. |
| Control Group | No intervention | –This group will not apply any cream and will skip all cream-related procedures during the study. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Physically healthy
- Age 18-45
- Available for 5 sessions over the span of 2 weeks
- Untrained (have not been participating in a structured resistance training routine for the past 2 months that includes 2 days of lower body resistance training per week)
Key exclusion criteria (3 listed)
- Have not suffered a lower body injury in the previous 3 months
- Be allergic to any ingredients within the CBD or placebo creams (ingredients listed in informed consent form)
- Be pregnant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cannabidiol creamAlso: Myaderm Advanced RX10 Fast Acting Relief CreamGroup 1 will be administered the recommended quantity of CBD cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method). | Other | CBD Group |
| Placebo creamAlso: Gold Bond Diabetics' Dry Skin Relief LotionGroup 2 will be administered the recommended quantity of placebo cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method). | Other | Placebo Group |
Primary outcome
Vertical Jump Test
Time frame: Baseline and immediately post exercise, then 24, 48, and 72 hours post-exercise (pre- and post-cream/rest).
The vertical jump, or countermovement jump (CMJ), test will utilize the ForceDecks Dual Force Plate System by Vald Performance to measure peak force production and vertical jump height (one plate for each leg; sampling frequency = 1,000 Hz).
2 secondary outcomes
Peak Isokinetic Torque Test
Time frame: Baseline and Session 5 (72 hours post-exercise)
Pressure-Pain Threshold Test
Time frame: Baseline and immediately post exercise, then 24, 48, and 72 hours post-exercise (pre- and post-cream/rest).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2024.
- Derived from this study: PubMed 38980809Pastina JT, Abel MG, Bollinger LM, Best SA. Topical Cannabidiol Application May Not Attenuate Muscle Soreness or Improve Performance: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study. Cannabis Cannabinoid Res. 2025 Jun;10(3):445-456. doi: 10.1089/can.2024.0012. Epub 2024 Jul 9.
Related trials for Muscle Soreness
Recruiting
Mineral-Infused Clothing for Recovery From Muscle Soreness and Muscle Damage After Exercise
Delayed Onset Muscle Soreness, Exercise-Induced Muscle Damage
Not yet recruiting
Clinical and MRI Characteristics of Delayed Onset Muscle Soreness (DOMS) of the Shoulder Rotator Muscles Induced by Eccentric Exercise: An Exploratory Prospective Experimental Study
Delayed Onset Muscle Soreness Experimentally Induced
Recruiting
Effects of Kinesio Tape on Delayed Onset Muscle Soreness
Delayed Onset Muscle Soreness
Not yet recruitingObservational study
A Study to Evaluate the Analgesic Properties of Topically Applied Menthol in Marathon Participants
Muscle Soreness
Not yet recruiting
Therapeutic Ultrasound for Muscle Recovery After Muscle Fatigue Exercise
Muscle Fatigue (C23.888.592.612.612), Delayed Onset Muscle Soreness (DOMS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stuart A Best, PhD principal investigator
University of Kentucky
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cannabidiol cream in people with Muscle Soreness, run by Joseph Pastina at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Vertical Jump Test (time frame: Baseline and immediately post exercise, then 24, 48, and 72 hours post-exercise (pre- and post-cream/rest).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06320327, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2024; AzTrials last refreshed its copy on 26 Oct 2026.